(no text — see the shared post below)

Empagliflozin reduced monocyte-platelet aggregates, hinting at vascular anti-inflammation
A Circulation pilot study led by Vanderbilt found participants treated with the SGLT2 inhibitor empagliflozin had reduced monocyte-platelet aggregates, clusters of immune cells and platelets linked to cardiovascular damage. It suggests diabetes drugs may also reduce vascular inflammation, though this is a small pilot.




